Prateek Sharma

Mr. Prateek Sharma

Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2022 in Pathophysiology
Verified
Journal Article
Open access
PDF file
APAjay Kumar Pal
Ajay Kumar Pal
PSPrateek Sharma
Prateek Sharma
AZAlishan Zia
Alishan Zia
DSDeepali Siwan
Deepali Siwan
DNDipali Nandave
Dipali Nandave
RGRupesh K Gautam
Rupesh K Gautam
Cancer cells undergo transient EMT and MET phenomena or vice versa, along with the parallel interplay of various markers, often correlated as the determining factor in decoding metabolic profiling of breast cancers. Moreover, various cancer signaling pathways and metabolic changes occurring in breast cancer cells modulate the expression of such markers to varying extents. The existing research completed so far considers the expression of such markers as determinants regulating the invasiveness and survival of breast cancer cells. Therefore, this manuscript is crosstalk among the expression levels of such markers and their correlation in regulating the aggressiveness and invasiveness of breast cancer. We also attempted to cover the possible EMT-based metabolic targets to retard migration and invasion of breast cancer.

1 December 2018 in Bioorganic Chemistry
Verified
Journal Article
Closed access
AKAvneet Kaur
Avneet Kaur
DPDharam P. Pathak
Dharam P. Pathak
VSVidushi Sharma
Vidushi Sharma
BNBalasubramanian Narasimhan
Balasubramanian Narasimhan
PSPrateek Sharma
Prateek Sharma
SWSharad Wakode
Sharad Wakode

29 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JNJayachandran Nair
Jayachandran Nair
TVThirumurthy Velpandian
Thirumurthy Velpandian
UDUjjalkumar Subhash Das
Ujjalkumar Subhash Das
PSPrateek Sharma
Prateek Sharma
TNTapas Chandra Nag
Tapas Chandra Nag
RMRajani Mathur
Rajani Mathur
The time course of pathogenesis of fructose mediated hepatic insulin resistance (HepIR) is not well-delineated and we chronicle it here from post-weaning to adulthood stages. Weaned rats were provided for either 4 or 8 weeks, i.e., upto adolescence or adulthood, chow + drinking water, chow + fructose, 15% or chow + fructose, 15% + hydroalcoholic extract of leaves of Aegle marmelos (AM-HM, 500 mg/kg/d, po) and assessed for feed intake, fructose intake, body weight, fasting blood sugar, oral glucose tolerance test, HOMA-IR, insulin tolerance test and lipid profile. Activities of enzymes (glucose-6-phosphatase, hexokinase, phosphofructokinase, aldehyde dehydrogenase), hormones (leptin, ghrelin, insulin), insulin signaling molecules (Akt-PI3k, AMPK, JNK) hallmarks of inflammation (TNF-α), angiogenesis (VEGF), hypoxia (HIF-1), lipogenesis (mTOR) and regulatory nuclear transcription factors of de novo lipogenesis and hepatic insulin resistance gene (SREBP-1, FoxO1) that together govern the hepatic fructose metabolism, were also studied. The effect of fructose-rich environment on metabolic milieu of hepatocytes was confirmed using (human hepatocellular carcinoma) HepG2 cells. Using in vitro model, fructose uptake and glucose output from isolated murine hepatocytes were measured to establish the HepIR under fructose environment and delineate the effect of AM-HM. The leaves from the plant Aegle marmelos (L) Correa were extracted, fractionated and validated for rutin content using LC-MS/MS. The rutin content of extract was quantified and correlated with oral pharmacokinetic parameters in rat. The outcomes of the study suggest that the molecular and metabolic markers of fructose induced HepIR in developing and adult rats are distinct. Further, AM-HM exerts a multi-pronged attack by raising insulin secretion, augmenting insulin action, improving downstream signaling of insulin, reducing overall requirement of insulin and modulating hepatic expression of glucose transporter (Glut2). The butanol fraction of AM-HM holds promise for future development.

1 August 2017 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HAH. Aggarwal
H. Aggarwal
JNJ. Nair
J. Nair
PSPrateek Sharma
Prateek Sharma
RSR. Sehgal
R. Sehgal
UNU. Naeem
U. Naeem
RMRajani Mathur
Rajani Mathur

25 April 2022
Verified
Preprint
Open access
PDF file
RMRajani Mathur
Rajani Mathur
PSPrateek Sharma
Prateek Sharma
JNJayachandran Nair
Jayachandran Nair
ASAnurag Sinh
Anurag Sinh
SCShivangi Chauhan
Shivangi Chauhan
RTRuchi Tripathi
Ruchi Tripathi
To develop hydroethanolic extract of leaves of Psidium guajava L. (Myrtaceae), identify novel target and lead compound for pediatric non alcoholic fatty liver disease (ped-NAFLD). Hydroethanolic extract (PG-HM) and sequential fractions of locally collected leaves of P.guajava were prepared and standardized for quercetin content using LC-MS/MS. The effect of PG-HM on markers of ped-NAFLD in weaned rats with unrestricted access to liquid fructose (15%) till puberty and early adulthood, was evaluated. The PG-HM was investigated using 1) HepG2 cells grown in fructose containing medium for intercellular signalling, 2) isolated murine hepatocytes for mitochondrial effects, 3) jejunum isolated from fructose drinking rats for effect on ex vivo fructose transport, 4) molecular dynamics for in silico binding of quercetin with GLUT5, 5) normal rats for oral pharmacokinetics. The quercetin content in PG-HM was 3630.66 ± 17.61 ng ml-1 and the Cmax and Tmax were 140.527 ± 5.718 ng ml-1 and 0.75 ± 0.079 h, respectively. The PG-HM mitigated ped-NAFLD through hepatic signalling pathways of 1) leptin-insulin (Akt/FOX-O1/SREBP-1c), 2) hypoxia-inflammation (HIF-1ɑ/VEGF, TNF-ɑ), 3) mitochondrial function (complexes I-V), 4) oxidative stress (MDA, GSH, SOD) and 5) glycolysis/gluconeogenesis/de novo lipogenesis (hexokinase, phosphofructokinase, ketohexokinase, aldehyde dehydrogenase). For the first time, the PG-HM is reported to reduce and delay the fructose transport across jejunum that may be implicated to the binding of quercetin with GLUT5. For prevention and treatment of ped-NAFLD, the PG-HM, GLUT5 and quercetin are evidenced as dietary supplement, drug target and lead compound, respectively.